Gunnar Fantoft, a 72-year-old entrepreneur from Aalborg, Denmark, emphasizes the critical role of early detection in fighting prostate cancer. He is married, has three children, and is a proud grandfather to five grandchildren. Gunnar founded his company, GF Inveco, in 1987 and continues to serve as its CEO today. Throughout his life, sports have been a vital aspect of his daily routine, and he still actively plays golf, tennis, and soccer.

Despite having no symptoms, Gunnar was advised by his doctor and friends to undergo a prostate-specific antigen (PSA) test. The PSA test is crucial for the early detection of prostate cancer, as it measures the concentration of PSA in the blood. Elevated levels can indicate the presence of prostate cancer.

In 2021, the PSA test revealed a very high value, prompting a PET-CT scan that confirmed his diagnosis of prostate cancer. He successfully underwent treatment with theranostics. During his treatment, Gunnar was classified as a super responder to this therapy, experiencing no side effects.

Gunnar chose not to hide his cancer diagnosis and actively shared information with patients and friends. To describe his therapy, he used a metaphor likening it to search for truffles, explaining that the radiopharmaceuticals would target tumors and metastases in the body, effectively destroying them. This analogy is easily to understand for many people.

With a positive outlook on life, Gunnar advises individuals to stay fit through exercise, not just when they are ill but at all times. Following his regular annual check-up in 2025, Susanne Simon, Head of Communications at the ICPO Foundation, had the pleasure of interviewing Gunnar at the ICPO office in Wiesbaden. Given his satisfaction with his patient journey, he is eager to support other cancer patients by sharing his experiences with radiotheranostics.